Список проголосовавших за комментарий " On The Wires<ul><li>Bravo Brio Restaurant Group (<strong>BBRG</strong>) acknowledged receipt and issued the following response to the letter sent to the Board of Directors by TAC Capital LLC on January 19, 2017. «Bravo Brio Restaurant Group is committed to executing a business strategy aligned with the best interests of the Company and all of its shareholders. The Company regularly engages in open and transparent dialogue with its investors and will always consider constructive input that helps drive long-term shareholder value.»</li><li>Lowe's Companies (<strong>LOW</strong>) announced that Jocelyn Wong has been appointed to the position of chief marketing officer, effective immediately. Wong most recently served as senior vice president and general merchandising manager for the seasonal business.</li><li>ORBCOMM Inc. (<strong>ORBC</strong>) selected by B.A.H. Express, Inc. (BAH) to provide an asset tracking solution for its dry van trailer fleet. B.A.H. expects to complete deployment of ORBCOMM's solution in 3Q17.</li><li>EnerNOC, Inc. (<strong>ENOC</strong>) announced that it will begin providing energy sourcing and advisory services in the recently de-regulated Mexican electricity market. One of EnerNOC's initial engagements in the region includes a procurement contract with a leading automotive systems and components supplier to design and manage a competitive energy sourcing process, as well as provide ongoing market intelligence and consulting services to optimize the company's energy budget and risk management strategy.</li><li>Finjan Holdings, Inc. (<strong>FNJN</strong>) announced that its subsidiary Finjan, Inc. filed a complaint on January 19, 2017 against its licensee, Avast Software (<strong>AVST</strong>), and its newly acquired company AVG Technologies, in the U.S. District Court for the Northern District of California (Case No. 3:17-cv-00283). Finjan is suing Avast for breach of contract and breach of the covenant of good faith and fair dealing; and both Avast and AVG for willful infringement of Finjan's patents, including U.S. Patent Nos. 6,154,844; 7,930,299; 7,975,305; 8,079,086; 8,141,154; and 8,677,494.</li><li>PositiveID Corporation (<strong>PSID</strong>) entered into a new distribution agreement with MedPro Associates. MedPro will market Caregiver primarily to the alternate site and long-term care markets, along with targeted acute care facilities.</li><li>Recon Technology, Ltd. (<strong>RCON</strong>) announced the recent delivery of furnace equipment to PetroChina Changqing Oilfield Company, China's largest oilfield company and a subsidiary of PetroChina (<strong>PTR</strong>).</li><li>Immune Pharmaceuticals Inc. (<strong>IMNP</strong>) announces that it has entered an exclusive sub-license agreement with SATT Sud-Est, a French Technology Transfer Office, to develop, use, manufacture and commercialize mono- and bispecific antibodies targeting components of the tumor microenvironment and angiogenic factors. The research program will be carried out under the responsibility of Inserm, National Center for Scientific Research, University Cote d'Azur, Scientific Center of Monaco, and Immune Pharmaceuticals.</li><li>Novelion Therapeutics Inc. (<strong>NVLN</strong>) announced that the European Medicines Agency has accepted for review the Marketing Authorization Application for metreleptin as replacement therapy to treat complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy and in a subset of patients with partial lipodystrophy. The MAA was filed in December 2016. An opinion from the Committee for Medicinal Products for Human Use is expected in December of 2017, and decision is expected in the first quarter of 2018.</li><li>A distribution agreement has been signed between Ewopharma and Biogen (<strong>BIIB</strong>) to market and sell the company's anti-Tumor Necrosis Factor (anti-TNF) biosimilars. Starting in 2017, Ewopharma will bring BENEPALI (etancercept) and FLIXABI (infliximab) to six countries, Romania, Bulgaria, Croatia, Estonia, Latvia and Lithuania. BENEPALI and FLIXABI are indicated to treat a number of inflammatory diseases, including Rheumatoid Arthritis, Psoriasis, Ankylosing Spondylitis and Inflammatory Bowel Disease.</li></ul>"